Reports Q3 revenue $216M, consensus $222.63M. “I am delighted that our strong operating performance and expense management throughout the year have resulted in an increase to EBITDA and non-GAAP EPS guidance. Today, we also announced an acceleration into this year of the remaining $250 million under the current approved $750 million share repurchase plan, authorized in 2021. This action is part of our disciplined and balanced approach to capital allocation and reflects our assessment that share repurchases today are a strong return on investment opportunity,” said Helen Torley, president and CEO of Halozyme. “Supporting our conviction in long-term revenue growth and durability, the third quarter was remarkable, with multiple, meaningful, de-risking events and progress for our upcoming series of Wave 3 potential product launches, projected for 2023-2025. I am also pleased with the progress in the quarter in advancing discussions on development of our HVAI.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- Acumen, Halozyme enter global collaboration, license agreement
- Halozyme enters non-exclusive license agreement with Acumen Pharmaceuticals
- HALO Upcoming Earnings Report: What to Expect?
- Halozyme confirms ‘positive’ results from Bristol Myers’ Phase 3 CheckMate-67T